Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -0.38
- Piotroski Score 2.00
- Grade Buy
- Symbol (GLYC)
- Company GlycoMimetics, Inc.
- Price $0.32
- Changes Percentage (-1.56%)
- Change -$0.01
- Day Low $0.31
- Day High $0.35
- Year High $3.53
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/15/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.58
- Trailing P/E Ratio -0.44
- Forward P/E Ratio -0.44
- P/E Growth -0.44
- Net Income $-36,899,420
Income Statement
Quarterly
Annual
Latest News of GLYC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Zealand Pharma Gets FDA Complete Response Letter for Hypoglycemia New Drug Application
Zealand Pharma received a complete response letter from the FDA regarding its new drug application for dasiglucagon to treat hypoglycemia in pediatric patients with congenital hyperinsulinism. The let...
By MarketWatch | 1 month ago -
Senior VP & Chief Medical Officer of GlycoMimetics Edwin Rock Buys 81% More Shares
GlycoMimetics' Senior VP & Chief Medical Officer bought $79k worth of stock, boosting their shareholding by 81%. Other insiders also purchased shares, indicating optimism. However, insider ownership i...
By Yahoo! Finance | 4 months ago
